Skip to main content

Raulerson Hospital Offering a Minimally Invasive Procedure for Patients with Enlarged Prostates

Raulerson Hospital December 15, 2016

Okeechobee, FL – Raulerson Hospital today announced that their Surgical Services Department is offering an innovative new treatment for benign prostatic hyperplasia (BPH), also known as enlarged prostate. Urologist, Dr. David Sigalow, is the first physician in the Treasure Coast to treat patients with this prostatic urethral lift system.

The urethral lift system is designed to relieve symptoms caused by an enlarged prostate, while preserving sexual function. Delivered during a minimally invasive procedure, the permanent prostatic urethral lift implants act like window curtain tie-backs to hold the lobes of an enlarged prostate open. Patients recover from the procedure quickly, and return to their normal routines with minimal downtime.

“We are committed to providing patients with the highest-quality, most effective options to address their urology needs,” said Dr. Sigalow who performed the first implants. “This system has an excellent safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery. Importantly, it provides fast and meaningful relief from BPH symptoms, improving overall quality of life for our patients.”

Benign prostatic hyperplasia (BPH), also known as enlarged prostate, affects more than 37 million men in the United States alone. Twelve times more common than prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Approximately one in four men experience BPH-related symptoms by age 55, with 90 percent of men over 70 symptomatic.

Data from clinical trials showed that patients receiving the urethral implants reported rapid symptomatic improvement, improved urinary flow rates, and sustained sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include blood in the urine, burning, pain, urination urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.

Raulerson Hospital is hosting a free Lunch & Learn event on Thursday, January 19th for the community to learn more about the minimally invasive prostatic urethral lift for BPH. Urologist, Dr. Sigalow, who performs the procedure, will be the guest speaker. The event will be held at the Indian River State College Campus in Okeechobee on January 19th from noon until 1:00 p.m. Lunch will be served. Attendees are asked to RSVP at RaulersonHosptial.com (classes and events) or by calling 763-9228.

About BPH Treatment
More than 500 million aging men worldwide have an enlarged prostate. Medication is often the first line therapy but relief can be inadequate and temporary. Side effects of treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra. While current surgical options, such as the 'gold standard' surgery, Transurethral Resection of the Prostate (TURP), can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, sexual dysfunction.

About the Prostatic Urethral Lift System
The FDA-cleared system is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving the implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include blood in the urine, burning, pain, urination urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. This system is available in the U.S., Europe, Australia and Canada.

News Related Content